PURPOSE: Tumors arising in the body/tail of the pancreas tend to be diagnosed at a more advanced stage, with a lower rate of resectability compared to disease of the head. Distal pancreatectomy (DP) associated to multivisceral resections (MVR) can represent a surgical option for selected patients with advanced tumors. METHODS: We retrospectively analyzed data of patients who underwent DP associated with MVR at our Institution over a 9-year period, and compared them to standard DP. MVR was defined as resection of at least one additional organ or vascular structure because of neoplastic involvement. RESULTS: Out of 508 DP, in 59 cases MVR was performed. The absolute incidence of complications was comparable between the two groups (69.5 % in MVR arm vs. 57.2 % in control arm, p = 0.072) but more patients in the study group had a Clavien-Dindo class ≥3 (18.6 vs. 9.8 %, p = 0.04). A longer operative time (291 ± 91 vs. 227 ± 67, p < 0.001), an increased need for intraoperative transfusions (21.4 vs. 3.3 %, p < 0.001) and a slightly longer hospitalization (9 [7-16] days vs. 8 [7-10]; p < 0.001) were observed in the MVR group. In patients with ductal adenocarcinoma (n = 118), mortality was comparable between groups (p = 0.44) over a median follow up of 26 [16-41] months. In contrast, among patients with neuroendocrine neoplasms, mortality was higher in the study group (p = 0.002). CONCLUSION: Multivisceral resection for cancer of body and tail of the pancreas is feasible in selected cases, with an acceptable surgical complication rate compared to standard procedures and a favorable long-term survival in ductal cancer.
PURPOSE: Tumors arising in the body/tail of the pancreas tend to be diagnosed at a more advanced stage, with a lower rate of resectability compared to disease of the head. Distal pancreatectomy (DP) associated to multivisceral resections (MVR) can represent a surgical option for selected patients with advanced tumors. METHODS: We retrospectively analyzed data of patients who underwent DP associated with MVR at our Institution over a 9-year period, and compared them to standard DP. MVR was defined as resection of at least one additional organ or vascular structure because of neoplastic involvement. RESULTS: Out of 508 DP, in 59 cases MVR was performed. The absolute incidence of complications was comparable between the two groups (69.5 % in MVR arm vs. 57.2 % in control arm, p = 0.072) but more patients in the study group had a Clavien-Dindo class ≥3 (18.6 vs. 9.8 %, p = 0.04). A longer operative time (291 ± 91 vs. 227 ± 67, p < 0.001), an increased need for intraoperative transfusions (21.4 vs. 3.3 %, p < 0.001) and a slightly longer hospitalization (9 [7-16] days vs. 8 [7-10]; p < 0.001) were observed in the MVR group. In patients with ductal adenocarcinoma (n = 118), mortality was comparable between groups (p = 0.44) over a median follow up of 26 [16-41] months. In contrast, among patients with neuroendocrine neoplasms, mortality was higher in the study group (p = 0.002). CONCLUSION: Multivisceral resection for cancer of body and tail of the pancreas is feasible in selected cases, with an acceptable surgical complication rate compared to standard procedures and a favorable long-term survival in ductal cancer.
Authors: Mehrdad Nikfarjam; Mandeep Sehmbey; Eric T Kimchi; Niraj J Gusani; Serene Shereef; Diego M Avella; Kevin F Staveley-O'Carroll Journal: J Gastrointest Surg Date: 2009-02-07 Impact factor: 3.452
Authors: Werner Hartwig; Charles M Vollmer; Abe Fingerhut; Charles J Yeo; John P Neoptolemos; Mustapha Adham; Ake Andrén-Sandberg; Horacio J Asbun; Claudio Bassi; Max Bockhorn; Richard Charnley; Kevin C Conlon; Christos Dervenis; Laureano Fernandez-Cruz; Helmut Friess; Dirk J Gouma; Clem W Imrie; Keith D Lillemoe; Miroslav N Milićević; Marco Montorsi; Shailesh V Shrikhande; Yogesh K Vashist; Jakob R Izbicki; Markus W Büchler Journal: Surgery Date: 2014-02-20 Impact factor: 3.982
Authors: A Cuschieri; S Weeden; J Fielding; J Bancewicz; J Craven; V Joypaul; M Sydes; P Fayers Journal: Br J Cancer Date: 1999-03 Impact factor: 7.640
Authors: Thijs de Rooij; Johanna A Tol; Casper H van Eijck; Djamila Boerma; Bert A Bonsing; Koop Bosscha; Ronald M van Dam; Marcel G Dijkgraaf; Michael F Gerhards; Harry van Goor; Erwin van der Harst; Ignace H de Hingh; Geert Kazemier; Joost M Klaase; I Quintus Molenaar; Gijs A Patijn; Hjalmar C van Santvoort; Joris J Scheepers; George P van der Schelling; Egbert Sieders; Olivier R Busch; Marc G Besselink Journal: Ann Surg Oncol Date: 2015-10-27 Impact factor: 5.344
Authors: Thomas Malinka; Fritz Klein; Andreas Andreou; Johann Pratschke; Marcus Bahra Journal: J Gastrointest Surg Date: 2018-05-10 Impact factor: 3.452
Authors: Oliver Beetz; Akin Sarisin; Alexander Kaltenborn; Jürgen Klempnauer; Michael Winkler; Gerrit Grannas Journal: World J Surg Oncol Date: 2020-08-20 Impact factor: 2.754